Dose and Schedule Study of Panitumumab Monotherapy in Patients with Advanced Solid Malignancies

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Clinical Cancer Research

• Publication date

  2008-01-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-07-1509PMID 18223225
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

  2007cited by this paper
• Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer

  2007cited by this paper
• Panitumumab activity in metastatic colorectal cancer (mCRC) patients (pts) with low or negative tumor epidermal growth factor receptor (EGFr) levels: An updated analysis

  2007cited by this paper
• Safety and pharmacokinetics (PK) of AMG 706, panitumumab, and gemcitabine/cisplatin (GC) for the treatment of advanced solid malignancies.

  2006cited by this paper
• Safety and pharmacokinetics (PK) of AMG 706, panitumumab, and carboplatin/paclitaxel (CP) for the treatment of patients (pts) with advanced non-small cell lung cancer (NSCLC).

  2006cited by this paper
• KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

  2006cited by this paper
• Cetuximab: adverse event profile and recommendations for toxicity management.

  2005cited by this paper
• Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study.

  2005cited by this paper
• Critical update and emerging trends in epidermal growth factor receptor targeting in cancer.

  2005cited by this paper
• Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer.

  2004cited by this paper
• Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

  2004cited by this paper
• Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.

  2004cited by this paper
• The presence and intensity of the cetuximab- induced acne-like rash predicts increased survival in studies across multiple malignances

  2003cited by this paper
• Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer.

  2003cited by this paper
• Epidermal growth factor receptor family in lung cancer and premalignancy.

  2002cited by this paper
• Untangling the ErbB signalling network

  2001influential reference
• Expression of the Tyrosine Kinase Activity Growth Factor Receptors (EGFR, ERB B2, ERB B3) in Colorectal Adenocarcinomas and Adenomas

  2000cited by this paper
• Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors.

  2000cited by this paper
• Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy.

  1999cited by this paper
• Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials.

  1997cited by this paper
• Epidermal growth factor-related peptides and their receptors in human malignancies.

  1995cited by this paper
• Receptor blockade with monoclomal antibodies as anti-cancer therapy

  1994cited by this paper
• Receptor blockade with monoclonal antibodies as anti-cancer therapy.

  1994cited by this paper
• EPIDERMAL GROWTH FACTOR BINDING BY MEMBRANES OF HUMAN RENAL CELL CARCINOMAS: ESTABLISHMENT OF AN EPIDERMAL GROWTH FACTOR RECEPTOR ASSAY FOR CLINICAL USE

  1994cited by this paper
• The immunohistochemical expressions of epidermal growth factors, epidermal growth factor receptors and c-erbB-2 oncoprotein in human pancreatic cancer.

  1992cited by this paper
• Signal transduction by receptors with tyrosine kinase activity.

  1990cited by this paper
• Epidermal growth factor receptor gene expression in normal human kidney and renal cell carcinoma.

  1989cited by this paper
• WHO Handbook for Reporting Results of Cancer Treatment

  1982cited by this paper
• Reporting results of cancer treatment

  1981cited by this paper

• A Tutorial on the Development of a Physiologically Inspired PKRO Model for Monoclonal Antibodies

  2025cites this paper
• Anti-EGFR Therapy in Metastatic Colorectal Cancer: Identifying, Tracking, and Overcoming Resistance

  2025influential citation
• Immunotherapy for colorectal cancer

  2024cites this paper
• Immunotherapy guided precision medicine in solid tumors.

  2024cites this paper
• Elucidating gastric cancer mechanisms and therapeutic potential of Adociaquinone A targeting EGFR: A genomic analysis and Computer Aided Drug Design (CADD) approach

  2024cites this paper
• Cetuximab every 2 weeks versus standard weekly dosing administration schedule.

  2023cites this paper
• Effectiveness and safety of capecitabine, irinotecan and panitumumab in advanced colorectal cancer

  2023cites this paper
• Safety and efficacy of anti-EGFR monoclonal antibody (SCT200) as second-line therapy in advanced esophageal squamous cell carcinoma

  2022cites this paper
• FBXW2 inhibits prostate cancer proliferation and metastasis via promoting EGFR ubiquitylation and degradation

  2022cites this paper
• Pharmacokinetics and pharmacodynamics of approved monoclonal antibody therapy for colorectal cancer

  2022cites this paper
• Safety, pharmacokinetics and efficacy of SCT200, an anti-EGFR monoclonal antibody in patients with wild-type KRAS/NRAS/BRAF metastatic colorectal cancer: a phase I dose-escalation and dose-expansion study

  2022cites this paper
• Panitumumab: A Review of Clinical Pharmacokinetic and Pharmacology Properties After Over a Decade of Experience in Patients with Solid Tumors

  2021influential citation
• A Review of Monoclonal Antibody-Based Treatments in Non-small Cell Lung Cancer.

  2021cites this paper
• A comprehensive review on immuno-nanomedicine for breast cancer therapy: Technical challenges and troubleshooting measures.

  2021cites this paper
• Chemotherapy and dysphagia: the good, the bad, the ugly

  2020cites this paper
• Immunology and Immunotherapy of Colorectal Cancer

  2020cites this paper
• Applications of Immunoglobulin Isotypes in Cancer Immunotherapy-A Review

  2020cites this paper
• A target‐mediated drug disposition population pharmacokinetic model of GC1118, a novel anti‐EGFR antibody, in patients with solid tumors

  2020cites this paper
• PET Theranostics for Molecular Imaging and Radioimmunotherapy of Pancreatic Cancer

  2019cites this paper
• Investigation of cytomegalovirus-based cancer vaccines

  2018cites this paper
• Panitumumab in the treatment of metastatic colorectal cancer, including wild-type RAS, KRAS and NRAS mCRC.

  2018cites this paper
• Development and validation of an ELISA to study panitumumab pharmacokinetics.

  2018cites this paper
• Clinical Pharmacokinetics and Pharmacodynamics of the Epidermal Growth Factor Receptor Inhibitor Panitumumab in the Treatment of Colorectal Cancer

  2017cites this paper
• Caractérisation topologique d'interactions non-covalentes inter- et intramoléculaires

  2017cites this paper
• First-Line Carboplatin, Pemetrexed, and Panitumumab in Patients with Advanced Non-Squamous KRAS Wild Type (WT) Non-Small-Cell Lung Cancer (NSCLC)

  2017cites this paper
• Classification of current anticancer immunotherapies

  2017cites this paper
• The Development Of A Novel Chimeric Antigen Receptor Specific For Syndecan-1

  2016cites this paper
• Second-line panitumumab as a triweekly dose for patients with wild-type KRAS exon 2 metastatic colorectal cancer: a single-institution experience

  2016cites this paper
• Antibody Therapies in Cancer.

  2016cites this paper
• Endocytic downregulation of the oncoproteins ErbB2 and ErbB3

  2016cites this paper
• Phase II trial of post-operative radiotherapy with concurrent cisplatin plus panitumumab in patients with high-risk, resected head and neck cancer.

  2016cites this paper
• Trial watch: Tumor-targeting monoclonal antibodies for oncological indications

  2015cites this paper
• Therapeutic Antibodies—Protein Engineering to Influence ADME, PK, and Efficacy

  2015cites this paper
• The Efficacy of Combining EGFR Monoclonal Antibody With Chemotherapy for Patients With Advanced Nonsmall Cell Lung Cancer

  2015cites this paper
• Profile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancer

  2015cites this paper
• Clinical features and risk factors of panitumumab-induced interstitial lung disease: a postmarketing all-case surveillance study

  2015cites this paper
• MicroPET/CT imaging of patient-derived pancreatic cancer xenografts implanted subcutaneously or orthotopically in NOD-scid mice using (64)Cu-NOTA-panitumumab F(ab')2 fragments.

  2015cites this paper
• Pharmacokinetic and pharmacodynamic evaluation of panitumumab in the treatment of colorectal cancer

  2015cites this paper
• Role of EGFR Monoclonal Antibodies in the Management of Non-small Cell Lung Cancer.

  2015cites this paper
• Current Status of Single-Agent Phase I Trials in Japan: Toward Globalization.

  2015cites this paper
• Impact of Diseases, Comorbidity, and Target Physiology on ADME, PK, and PK/PD of Therapeutic Biologics

  2015cites this paper
• Review Article Immunotherapy for colorectal cancer

  2015cites this paper
• Trial Watch

  2014cites this paper
• Classification of current anticancer immunotherapies

  2014cites this paper
• Pharmacokinetics of panitumumab in a patient with liver dysfunction: a case report

  2014cites this paper
• Trial Watch

  2014cites this paper
• Panitumumab in Japanese Patients with Unresectable Colorectal Cancer: A Post-marketing Surveillance Study of 3085 Patients†

  2014cites this paper
• A 3-weekly schedule of irinotecan and panitumumab for wild-type KRAS metastatic colorectal cancer

  2014cites this paper
• Panitumumab safety for treating colorectal cancer

  2014cites this paper
• Impact of 5-fluorouracil metabolizing enzymes on chemotherapy in patients with resectable colorectal cancer

  2014cites this paper
• Immunotherapy in Cancer Treatment

  2014cites this paper
• Panitumumab: leading to better overall survival in metastatic colorectal cancer?

  2014cites this paper
• Panitumumab (Vectibix®): A Treatment for Metastatic Colorectal Cancer

  2014cites this paper
• 進行・再発の結腸・直腸癌に対するパニツムマブ投与時の皮膚障害発現についての検討―パニツムマブ特定使用成績調査のサブ解析―

  2014cites this paper
• Panitumumab in the treatment of colon cancer: A biomarker dilemma.

  2014cites this paper
• Phase III Trials of Targeted Anticancer Therapies: Redesigning the Concept

  2013cites this paper
• "Chronic" metastatic pancreatic acinar cell carcinoma.

  2013cites this paper
• A Phase 2 Randomized Trial of Paclitaxel and Carboplatin with or without Panitumumab for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

  2013cites this paper
• Relationship between expression of EGFR in gastric cancer tissue and clinicopathological features.

  2013cites this paper
• Increasing chemotherapeutic and targeted drug options has led to improved overall survival in metastatic colorectal cancer. Panitumumab is a fully humanized monoclonal antibody that binds to the EGF receptor and inhibits downstream cell signaling with net effects

  2013cites this paper
• Trial watch

  2013cites this paper
• Panitumumab and irinotecan every 3 weeks is an active and convenient regimen for second-line treatment of patients with wild-type K-RAS metastatic colorectal cancer

  2013cites this paper
• Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial

  2013cites this paper
• Panitumumab in metastatic colorectal cancer

  2013cites this paper
• Molecularly Targeted Therapies in Metastatic Pancreatic Cancer: A Systematic Review

  2013cites this paper
• Targeting receptor tyrosine kinases in solid tumors.

  2013cites this paper
• Maximum-tolerated dose, optimum biologic dose, or optimum clinical value: dosing determination of cancer therapies.

  2012cites this paper
• Long-Term Treatment of Metastatic Colorectal Cancer with Panitumumab

  2012cites this paper
• Monoclonal Antibodies: An Emerging Class of Therapeutics in Non Small Cell Lung Cancer

  2012cites this paper
• Monoclonal antibodies for the treatment of cancer.

  2012cites this paper
• Progress of molecular targeted therapies for prostate cancers.

  2012cites this paper
• Tumor penetration and epidermal growth factor receptor saturation by panitumumab correlate with antitumor activity in a preclinical model of human cancer

  2012cites this paper
• Trial Watch: Monoclonal antibodies in cancer therapy

  2012cites this paper
• Anti‐EGFR Monoclonal Antibodies for Treatment of Colorectal Cancers: Development of Cetuximab and Panitumumab

  2012influential citation
• Panitumumab: a summary of clinical development in colorectal cancer and future directions.

  2012influential citation
• Leczenie celowane u chorych na raka gruczołu krokowego

  2012cites this paper
• Panitumumab in combination with cytotoxic chemotherapy for the treatment of metastatic colorectal carcinoma.

  2012cites this paper
• Efficacy of Cetuximab in Metastatic Castration-Resistant Prostate Cancer Might Depend on EGFR and PTEN Expression: Results from a Phase II Trial (SAKK 08/07)

  2012cites this paper
• Folliculitis induced by EGFR inhibitors, preventive and curative efficacy of tetracyclines in the management and incidence rates according to the type of EGFR inhibitor administered: a systematic literature review.

  2012cites this paper
• Selection and characterization of cell binding and internalizing phage antibodies.

  2012cites this paper
• Expression pattern and targeting of HER family members and IGF-IR in pancreatic cancer.

  2012cites this paper
• MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib.

  2011cites this paper
• Effective antibody therapy induces host-protective antitumor immunity that is augmented by TLR4 agonist treatment

  2011cites this paper
• Optimal integration of EGFR inhibitors in advanced colorectal cancer

  2011cites this paper
• Cancer immunotherapy.

  2011cites this paper
• Engineering Antibodies for Cancer Therapy

  2011cites this paper
• Oral complications of targeted cancer therapies: a narrative literature review.

  2011cites this paper
• Epidermal Growth Factor Receptor Inhibitors in the Treatment of Nonmelanoma Skin Cancers

  2011cites this paper
• Targeted therapy in colorectal cancer: current status and future challenges.

  2011cites this paper
• Antibody expression and production

  2011cites this paper
• Direct discovery and validation of a peptide/MHC epitope expressed in primary human breast cancer cells using a TCRm monoclonal antibody with profound antitumor properties

  2010cites this paper
• Efficacy of the monoclonal antibody EGFR inhibitors for the treatment of metastatic colorectal cancer

  2010cites this paper
• Panitumumab: the evidence for its use in the treatment of metastatic colorectal cancer

  2010cites this paper
• Consensus recommendations for the use of anti-egfr therapies in metastatic colorectal cancer.

  2010cites this paper
• Monoclonal antibodies: versatile platforms for cancer immunotherapy

  2010cites this paper
• Integration of Anti-Epidermal Growth Factor Receptor Therapies With Cytotoxic Chemotherapy

  2010cites this paper
• Drug development in advanced esophagogastric cancer: the art of extrapolation.

  2010cites this paper
• Novel agents in the management of lung cancer.

  2010cites this paper
• Pharmacokinetic and Pharmacodynamic Perspectives on the Clinical Drug Development of Panitumumab

  2010cites this paper
• Panitumumab: An Arrow on Target

  2010cites this paper